drugset / Trial / NCT05135845
Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Immunotherapy with anti-PD1 antibodies provides encouraging results on a subset of patients. Capmatinib, a MET inhibitor, has shown an imunomodulatory effect and a synergy with spartalizumab a PD-1 inhibitor. The purpose of this phase II trial is to evaluate the efficacy and safety of the combination of capmatinib + spartalizumab in adult patients with advanced oesogastric adenocarcinoma.
Timeline
- Start
- 2022-03-22
- Primary completion
- 2023-04
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capmatinib | Small molecule | 400 mg | — |
| Subject | Spartalizumab | Monoclonal antibody | 300 mg | — |